President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe Biden’s other historic policy accomplishments.
But Trump will likely make some changes to those price talks, and it may not require help from Congress.
“Trump is looking to nibble around the edges of the law,” said Matthew Kupferberg, a partner in Frier Levitt’s Life Sciences Group, adding that the president is “not looking to completely abandon the drug negotiation process at this point.”
It’s still unclear which way Trump will lean, however. While some lawmakers and health policy experts said Trump could weaken the negotiations in a way that helps the pharmaceutical industry, other experts said he could double down and try to save patients and the federal government even more money to outdo his predecessor.